Advancements made in medical oncology in the metastatic setting are now being used to benefit melanoma patients with Stage III disease. In this podcast, Medical Oncologist A/Prof Menzies is interviewed by A/Prof Carlino on how adjuvant (postoperative) therapy is being used in melanoma to eradicate occult metastatic disease to reduce the chances of recurrence. They discuss the role of immunotherapy and targeted therapy in the adjuvant setting, and mention how systemic therapy is being trialled in the neoadjuvant (preoperative) space.
This podcast is suitable medical oncologists, surgical oncologists and radiation oncologists, and may also be of interest to GPs, oncology nurses and other healthcare practitioners.
PRESENTERSA/Prof Alexander MenziesMedical Oncologist, Melanoma Institute Australia, Royal North Shore and Mater Hospitals | Associate Professor of Melanoma Medical Oncology, The University of Sydney
A/Prof Matteo CarlinoMedical Oncologist, Melanoma Institute Australia, Westmead and Blacktown Hospitals | Clinical Associate Professor, The University of Sydney
LEARNING OUTCOMES1. Identify patients at high risk of recurrence or relapse following resection of melanoma.2. Recall the evidence supporting the use of immune checkpoint inhibitors and targeted therapy as adjuvant therapy in melanoma.3. Outline current recommendations for adjuvant therapy in melanoma.